Skip to main content
OpenTrials

Clinical trial condition

Meningococcal Infections

Explore clinical trials studying Meningococcal Infections. Study availability and eligibility vary by location and protocol.

216 public trials 4 recruiting studies
Refine in advanced search Browse all conditions

Meningococcal Infections trial results

Completed

Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.

NCT01682876

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Sacramento, California, United States
  • GSK Investigational Site Lake Mary, Florida, United States
  • GSK Investigational Site Marietta, Georgia, United States
View all 19 locations
View Trial Details
Completed

The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination

NCT01962207

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • Espoo Vaccine Research Clinic Espoo, Finland
  • South Helsinki Vaccine Research Clinic Helsinki, Finland
  • Helsinki East Vaccine Research Clinic Helsinki, Finland
  • Jarvenpaa Vaccine Research Clinic Jarvenpaa, Finland
View Trial Details
Completed

Study to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life

NCT00625677

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +6 more
Locations
  • Health Protection Agency Gloucester, United Kingdom
  • Health Protection Agency London, United Kingdom
View Trial Details
Completed

Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules

NCT00661713

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • Site 13: Liceo Diego Aracena de Lo Barnechea Monseñor Escrivá de Balaguer 14630, Lo Barnechea, Santiago Metropolitan, Chile
  • Site 41: Colegio Antonio Hermida Fabres Av. Coronel Alejandro Sepúlveda N° 6801, Chile
  • Site 43: Liceo José Victorino Lastarria Av. Miguel Claro N° 32, Chile
  • Site 51: Centro Para vacunas en Desarrollo. Hospital de Niños Roberto del Rio Av. Prof Zañartu 1085, Chile
View Trial Details
Completed

Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination

NCT01777308

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • GSK Investigational Site Garran, Australian Capital Territory, Australia
  • GSK Investigational Site Randwick, New South Wales, Australia
  • GSK Investigational Site Westmead, New South Wales, Australia
  • GSK Investigational Site Herston, Queensland, Australia
View Trial Details
Completed

Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine

NCT00508261

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • GSK Investigational Site Eferding, Austria
  • GSK Investigational Site Neufeld/Leitha, Austria
  • GSK Investigational Site Salzburg, Austria
  • GSK Investigational Site Villach, Austria
View all 89 locations
View Trial Details
Completed

Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A

NCT00496015

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Body Temperature Changes, +11 more
Locations
  • GSK Investigational Site Brno, Czechia
  • GSK Investigational Site Hradec Králové, Czechia
  • GSK Investigational Site Jindřichův Hradec, Czechia
  • GSK Investigational Site Náchod, Czechia
View Trial Details
Completed

Combined Study - Phase 3b MenB Long Term Persistence in Adolescents

NCT02446743

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Central Nervous System Diseases, +8 more
Locations
  • GSK Investigational Site Sherwood, Queensland, Australia
  • GSK Investigational Site North Adelaide, South Australia, Australia
  • GSK Investigational Site Carlton, Victoria, Australia
  • GSK Investigational Site Subiaco, Western Australia, Australia
View Trial Details

Related conditions